| Literature DB >> 33768646 |
Daniel A Wirtz1, Kevin C Ludwig2,3, Melina Arts2, Carina E Marx2, Sebastian Krannich2, Paul Barac1, Stefan Kehraus1, Michaele Josten3,4, Beate Henrichfreise2, Anna Müller2, Gabriele M König1, Aaron J Peoples5, Anthony Nitti5, Amy L Spoering5, Losee L Ling5, Kim Lewis6, Max Crüsemann1, Tanja Schneider2.
Abstract
Hypeptin is a cyclodepsipeptide antibiotic produced by Lysobacter sp. K5869, isolated from an environmental sample by the iChip technology, dedicated to the cultivation of previously uncultured microorganisms. Hypeptin shares structural features with teixobactin and exhibits potent activity against a broad spectrum of gram-positive pathogens. Using comprehensive in vivo and in vitro analyses, we show that hypeptin blocks bacterial cell wall biosynthesis by binding to multiple undecaprenyl pyrophosphate-containing biosynthesis intermediates, forming a stoichiometric 2:1 complex. Resistance to hypeptin did not readily develop in vitro. Analysis of the hypeptin biosynthetic gene cluster (BGC) supported a model for the synthesis of the octapeptide. Within the BGC, two hydroxylases were identified and characterized, responsible for the stereoselective β-hydroxylation of four building blocks when bound to peptidyl carrier proteins. In vitro hydroxylation assays corroborate the biosynthetic hypothesis and lead to the proposal of a refined structure for hypeptin.Entities:
Keywords: antibiotic; cell wall; cyclodepsipeptide; hydroxylase; lipid II
Year: 2021 PMID: 33768646 DOI: 10.1002/anie.202102224
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336